SGLT2 inhibitors are a relatively new but valuable class of drugs that, besides the anti-hyperglycemic action, demonstrated cardiovascular and renal benefits, even in individuals without diabetes; consequently, treatment regimens combining SGLT2 inhibitors with other oral antidiabetic drugs represent an appropriate therapeutic option for patients presenting cardiovascular or renal comorbidities, and is recommended by current guidelines for those with a history of cardiovascular disease, or at high risk for it, as well as for patients with chronic kidney disease. The gene discussed is SLC5A2; the disease is cardiovascular disorder.